Search

Displaying results 5641 - 5650 of 10000 in total
  1. Drug

    Cladosporium herbarum

    go.drugbank.com/drugs/DB10865
    Approved

    Cladosporium herbarum extract is used in allergenic testing.

  2. Drug

    Chrysonilia sitophila

    go.drugbank.com/drugs/DB10935
    Approved

    Chrysonilia sitophila extract is used in allergenic testing.

  3. Drug

    Aspergillus nidulans

    go.drugbank.com/drugs/DB11022
    Approved

    Aspergillus nidulans extract is used in allergenic testing.

  4. Drug

    Dendryphiella vinosa

    go.drugbank.com/drugs/DB11025
    Approved

    Dendryphiella vinosa extract is used in allergenic testing.

  5. Drug

    Nitarsone

    go.drugbank.com/drugs/DB11437
    ExperimentalVet approved

    Nitarsone is an organoarsenic compound. It is used as an additive in poultry feed to improve weight gain and feed efficiency, while preventing blackhead disease.

  6. Drug

    Pamiparib

    go.drugbank.com/drugs/DB14769
    Investigational

    on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy). … Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression

  7. Drug

    Lutetium (177Lu) NeoB

    go.drugbank.com/drugs/DB30389
    Investigational

    Lutetium (177Lu) NeoB is under investigation in clinical trial NCT06379217 (NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine

  8. Drug

    Tovinontrine

    go.drugbank.com/drugs/DB16193
    Investigational

    Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell Disease). … Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor.

  9. Drug

    Zilebesiran

    go.drugbank.com/drugs/DB18929
    Investigational

    Zilebesiran is under investigation in clinical trial NCT06272487 (Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care

  10. Drug

    XR5944

    go.drugbank.com/drugs/DB06364
    Experimental

    XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.